Results 151 to 160 of about 2,130,247 (378)

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

, 2020
Adam J. Schoenfeld, Chai Bandlamudi, Jessica A. Lavery, Joseph Montecalvo, Azadeh Namakydoust, Hira Rizvi, Jacklynn V. Egger, Carla P. Concepcion, Sonal Paul, Maria E. Arcila, Yahya Daneshbod, Jason C. Chang, Jennifer L. Sauter, Amanda Beras, Marc Ladanyi, Tyler Jacks, Charles M. Rudin, Barry S. Taylor, Mark T.A. Donoghue, Glenn Heller, Matthew D. Hellmann, Natasha Rekhtman, Gregory J. Riely   +22 more
openalex   +2 more sources

GenPipes: an open-source framework for distributed and scalable genomic analyses [PDF]

, 2019
Mathieu Bourgey, Rola Dali, Robert Eveleigh, Kuang Chung Chen, Louis Létourneau, Joël Fillon, Marc Michaud, Maxime Caron, Johanna Sandoval, François Lefebvre, Gary Leveque, Eloi Mercier, David Bujold, Pascale Marquis, Patrick Tran Van, David Anderson de Lima Morais, Julien Tremblay, Xiaojian Shao, Édouard Henrion, Emmanuel González, Pierre-Olivier Quirion, B. Caron, Guillaume Bourque   +22 more
openalex   +1 more source

Genomic analysis reveals a cryptic pangolin species [PDF]

, 2023
Tong‐Tong Gu, Hong Wu, Feng Yang, Philippe Gaubert, Sean P. Heighton, Yeyizhou Fu, Ke Liu, Shu‐Jin Luo, Huarong Zhang, Jingyang Hu, Li Yu   +10 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics [PDF]

, 2019
Mark R. Davies, Liam McIntyre, Ankur Mutreja, Jake A. Lacey, John A. Lees, Rebecca J. Towers, Sebastián Duchêne, Pierre R. Smeesters, Hannah R. Frost, David J. Price, Matthew T. G. Holden, Sophia David, Philip M. Giffard, Kate A. Worthing, Anna C. Seale, James A. Berkley, Simon R. Harris, Tania Rivera-Hernández, Olga Berking, Amanda J. Cork, Rosângela S. L. A. Torres, Trevor Lithgow, Richard A. Strugnell, René Bergmann, Patric Nitsche-Schmitz, G. S. Chhatwal, Stephen D. Bentley, John D. Fraser, Nicole J. Moreland, Jonathan R. Carapetis, Andrew C. Steer, Julian Parkhill, Allan Saul, Deborah A. Williamson, Bart J. Currie, Steven Y. C. Tong, Gordon Dougan, Mark J. Walker   +37 more
openalex   +1 more source

Integrating High-Throughput Phenotyping and Statistical Genomic Methods to Genetically Improve Longitudinal Traits in Crops [PDF]

, 2020
Fabiana Freitas Moreira, Hinayah Rojas de Oliveira, Jeffrey J. Volenec, Katy Martin Rainey, Luiz F. Brito   +4 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Recent novel approaches for population genomics data analysis [PDF]

, 2014
Kimberly R. Andrews, Gordon Luikart
openalex   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source